Sermorelin 10mg
Original price was: 54,99 €.43,99 €Current price is: 43,99 €.
Email when stock available
Sermorelin Europe Sermorelin Peptide · GRF(1-29)-NH? · Native GHRH Fragment
Sermorelin Europe is supplied by Baltic Peptides as a lyophilised research peptide at ≥99% analytical purity, verified per batch by independent HPLC and mass spectrometry. The Sermorelin peptide (GRF 1-29) is a synthetic 29-residue amide identical to amino acids 1–29 of human growth hormone-releasing hormone, GHRH(1-44): the shortest fragment that keeps the full receptor activity of the native hormone.
Because it carries no stabilising substitutions, Sermorelin is the unmodified reference compound against which engineered GHRH analogues such as CJC-1295 and Tesamorelin are compared. It activates the pituitary GHRH receptor (GHRH-R) and is cleared within minutes, giving a short, pulse-like GH response in research models. Researchers looking for Sermorelin EU supply receive it dispatched from Lithuania with a batch COA.
Supplied exclusively for in vitro and preclinical research by qualified investigators and licensed research institutions.
Third-Party Verified · COA Available · EU Dispatch
Analytical Purity
HPLC · Mass Spec Verified
Key Features
If you buy Sermorelin Europe from Baltic Peptides, you receive a ≥99% HPLC-verified, independently tested Sermorelin peptide dispatched from within the EU.
-
Purity — ≥99% by HPLC analysis
-
Form — Lyophilised powder, single vials
-
Storage (long-term) — −20 °C, desiccated, protected from light
-
Storage (short-term) — 2–8 °C, up to 4 weeks
-
Solubility — Sterile water, bacteriostatic water or dilute acetic acid (≥1 mg/mL)
-
Classification — Research Use Only (RUO)
-
Testing — Independent third-party batch verification
-
Documentation — Certificate of Analysis per batch
Scientific Overview — Sermorelin Europe
Compound Background
Discovery & Regulatory History
GHRH was isolated in 1982 by Roger Guillemin’s group and by Wylie Vale and Jean Rivier’s group, from pancreatic tumours that were overproducing it. The 44-residue hormone was soon shown to keep its full GH-releasing activity when shortened to residues 1–29, and that amidated fragment became sermorelin.
Sermorelin acetate was marketed by Serono as Geref, approved by the FDA in the 1990s for diagnostic testing of pituitary GH reserve and for paediatric GH deficiency, and withdrawn from the market in 2008 for manufacturing reasons rather than safety. That clinical history left an unusually large body of published pharmacokinetic data for a GHRH-class compound.
Mechanism: GHRH Receptor Agonism
Sermorelin binds the pituitary GHRH receptor, a Gs-coupled GPCR on somatotroph cells. Receptor activation raises cAMP, which drives GH gene transcription and calcium-dependent GH release. Because Sermorelin has no protective modifications, the enzyme DPP-4 quickly cleaves its Tyr1–Ala2 bond, and its plasma half-life is only about 10–20 minutes. That short exposure produces a sharp, pulse-like GH signal in research models.
Sermorelin Half-Life in Context
~10–20 min
~30 min
~25–40 min
~6–8 days
Bar widths are illustrative. The engineered analogues extend half-life by blocking DPP-4 cleavage (D-Ala2 in CJC-1295; an N-terminal hexenoyl group in Tesamorelin) or by binding albumin (DAC).
Sermorelin vs Engineered GHRH Analogues
| Parameter | Sermorelin | CJC-1295 No DAC | CJC-1295 with DAC |
|---|---|---|---|
| Length | 29 residues | 29 residues | 29 + Lys-DAC |
| Substitutions vs native | None (native) | D-Ala2, Gln8, Ala15, Leu27 | Same four + DAC linker |
| DPP-4 resistance | No | Yes | Yes |
| Met27 oxidation risk | Yes | No (Leu27) | No (Leu27) |
| Half-life | 10–20 min | 30 min | 6–8 days |
| Typical research role | Native reference / positive control | Stabilised pulsatile tool | Sustained-exposure tool |
Primary Research Domains
Signalling Pathway — Research Context
Sermorelin GRF(1-29)
GHRH-R · Gs
cAMP · PKA · Ca²⁺
Pulsatile GH Release
Technical Specifications — Sermorelin Europe
| Parameter | Specification |
|---|---|
| Compound Name | Sermorelin (GRF 1-29; GHRH(1-29)-NH2) |
| Compound Class | Native GHRH fragment; GHRH-R agonist |
| Sequence | YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2 |
| Molecular Formula | C149H246N44O42S |
| Molecular Weight | 3357.9 g/mol |
| CAS Number | 86168-78-7 |
| Oxidation-Sensitive Residue | Met27 (native) |
| Purity | ≥99% (HPLC verified per batch) |
| Form / Appearance | White lyophilised powder |
| Solubility | Sterile water, bacteriostatic water or dilute acetic acid (≥1 mg/mL) |
| Long-Term Storage | −20 °C, desiccated, protected from light |
| Short-Term Storage | 2–8 °C, sealed vial, up to 4 weeks |
| Reconstituted Stability | Up to 14 days at 2–8 °C; avoid freeze-thaw cycling |
| Research Classification | Research Use Only (RUO) |
| Supplier | Baltic Peptides — EU dispatch from Lithuania |
Sermorelin Europe — Lab Testing & Quality Assurance
Each batch is independently tested before release and published per lot on our COA page.
HPLC Purity Analysis
Reverse-phase HPLC confirms ≥99% purity, with specific monitoring for the Met27-sulfoxide variant and truncated sequences.
Mass Spectrometry
ESI-MS confirms the expected 3357.9 Da mass of the intact 29-residue amide and checks for the +16 Da oxidised form.
Certificate of Analysis
A batch-specific COA documents purity, identity, lot number, testing dates and method references.
Third-Party Verification
Analytical data is generated by independent external laboratories for auditable, conflict-free documentation.
Storage & Handling — Sermorelin Europe
Because Sermorelin Europe keeps the native Met27, protect it from light and air at every stage, as with other methionine-containing peptides. See our cold-chain storage guide.
Lyophilised (Unopened)
−20 °C, desiccated. Stable for 24 months from manufacture. Protect from light and moisture.
Short-Term (Unopened)
2–8 °C for up to 4 weeks in the sealed vial.
Reconstituted Solution
2–8 °C, closed and light-protected. Use within 14 days. Avoid freeze-thaw cycling. Use amber or foil-wrapped vials.
Reconstitution
Add solvent slowly down the vial wall and swirl gently — do not vortex. Method as in our peptide reconstitution guide.
Related Research Reading
Further reading from the Baltic Peptides Research Library:
Research Use Only — Important Notice
All products supplied by Baltic Peptides are designated exclusively for in vitro research, preclinical investigation, and laboratory study by qualified professionals operating within appropriately licensed or regulated research environments.
Sermorelin Europe is a research-grade reagent. Although sermorelin was previously marketed as a licensed medicine (Geref, discontinued 2008), the material supplied here is not a medicinal product, is not approved for human or veterinary use, and is not intended for self-administration or any use outside controlled scientific research.
By completing a purchase, the buyer confirms their status as a qualified researcher and acknowledges the research-use-only classification of this compound. Baltic Peptides assumes no liability for any use beyond its stated research designation.
Frequently Asked Questions — Sermorelin Europe
What is Sermorelin?
Sermorelin (GRF 1-29) is a synthetic peptide identical to the first 29 amino acids of human GHRH, with a C-terminal amide. Its formula is C149H246N44O42S, molecular weight 3357.9 g/mol and CAS number 86168-78-7. Baltic Peptides supplies Sermorelin in Europe at ≥99% purity.
Where can I buy Sermorelin in the EU?
You can buy Sermorelin Europe directly from Baltic Peptides. Orders are dispatched from Lithuania with tracked shipping across the EU and a batch-specific Certificate of Analysis, for research use only.
What is the Sermorelin peptide used for in research?
It is the native reference agonist for the GHRH receptor: a positive control in binding and cAMP assays, a baseline in structure–activity studies of stabilised analogues, and a tool for modelling short GHRH pulses and pituitary reserve in animal models.
How does Sermorelin differ from CJC-1295 No DAC?
CJC-1295 No DAC is the same 29-residue fragment with four substitutions (D-Ala2, Gln8, Ala15, Leu27). These block DPP-4 cleavage and remove the oxidation-prone Met27, roughly doubling half-life to about 30 minutes. Sermorelin is the unmodified native sequence.
Why does Sermorelin need light protection?
It keeps the natural methionine at position 27, which oxidises to methionine sulfoxide on exposure to light and oxygen. Store it cold, dark and dry, and use reconstituted solutions within 14 days.
Is Sermorelin an approved medicine?
Not currently. It was marketed as Geref until 2008, when it was withdrawn for manufacturing reasons. It has no current EMA or FDA approval.
Is a Certificate of Analysis available for Sermorelin Europe?
Yes. Every lot comes with a batch-specific COA documenting purity, identity, lot number and testing dates, published on the Baltic Peptides COA page.
What are the shipping conditions for Sermorelin Europe?
Sermorelin Europe ships from Lithuania, giving shorter transit times and no non-EU customs exposure for European researchers. Orders are packed with temperature- and light-protective materials and fully tracked. See our shipping page.





